Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Challenges in drug target discovery in bipolar disorder.

Alsaif M, Haenisch F, Guest PC, Rahmoune H, Bahn S.

Expert Opin Ther Targets. 2013 May;17(5):565-77. doi: 10.1517/14728222.2013.771169. Epub 2013 Feb 18. Review.

PMID:
23419165
2.

Novel routes to bipolar disorder drug discovery.

Hoertel N, de Maricourt P, Gorwood P.

Expert Opin Drug Discov. 2013 Aug;8(8):907-18. doi: 10.1517/17460441.2013.804057. Epub 2013 May 27. Review.

PMID:
23706065
3.

Epigenetic approaches for bipolar disorder drug discovery.

Peedicayil J.

Expert Opin Drug Discov. 2014 Aug;9(8):917-30. doi: 10.1517/17460441.2014.922537. Epub 2014 May 29. Review.

PMID:
24875048
4.

Drugs under early investigation for the treatment of bipolar disorder.

Konstantakopoulos G, Dimitrakopoulos S, Michalopoulou PG.

Expert Opin Investig Drugs. 2015 Apr;24(4):477-90. doi: 10.1517/13543784.2015.1019061. Epub 2015 Feb 23. Review.

PMID:
25704484
5.

β-catenin promoter ChIP-chip reveals potential schizophrenia and bipolar disorder gene network.

Pedrosa E, Shah A, Tenore C, Capogna M, Villa C, Guo X, Zheng D, Lachman HM.

J Neurogenet. 2010 Dec;24(4):182-93. doi: 10.3109/01677063.2010.495182. Epub 2010 Jul 8.

PMID:
20615089
6.

Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?

Fornaro M, Aguglia E, Dell'Osso L, Perugi G.

Expert Opin Pharmacother. 2011 Dec;12(18):2817-31. doi: 10.1517/14656566.2011.632366. Review.

PMID:
22098226
7.

Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.

Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK.

Mol Psychiatry. 2004 Aug;9(8):734-55. Review.

PMID:
15136794
8.

Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.

Gould TD, Zarate CA, Manji HK.

J Clin Psychiatry. 2004 Jan;65(1):10-21. Review.

PMID:
14744163
9.

A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder.

McEachin RC, Chen H, Sartor MA, Saccone SF, Keller BJ, Prossin AR, Cavalcoli JD, McInnis MG.

BMC Syst Biol. 2010 Nov 19;4:158. doi: 10.1186/1752-0509-4-158.

10.

Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder.

McEachin RC, Saccone NL, Saccone SF, Kleyman-Smith YD, Kar T, Kare RK, Ade AS, Sartor MA, Cavalcoli JD, McInnis MG.

BMC Med Genet. 2010 Jan 26;11:14. doi: 10.1186/1471-2350-11-14.

11.

The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania.

Tarazi FI, Neill JC.

Expert Opin Drug Discov. 2013 Jan;8(1):93-103. doi: 10.1517/17460441.2013.738193. Epub 2012 Nov 4. Review.

PMID:
23121334
12.

Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.

Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr.

CNS Spectr. 2013 Oct;18(5):242-51. doi: 10.1017/S1092852913000138. Epub 2013 Mar 11. Review.

13.

Reverse translational strategies for developing animal models of bipolar disorder.

Malkesman O, Austin DR, Chen G, Manji HK.

Dis Model Mech. 2009 May-Jun;2(5-6):238-45. doi: 10.1242/dmm.001628. Review.

14.

Therapeutic use of omega-3 fatty acids in bipolar disorder.

Balanzá-Martínez V, Fries GR, Colpo GD, Silveira PP, Portella AK, Tabarés-Seisdedos R, Kapczinski F.

Expert Rev Neurother. 2011 Jul;11(7):1029-47. doi: 10.1586/ern.11.42. Review.

PMID:
21721919
15.

[Neuropatological and neurochemical abnormalities in bipolar disorder].

Frey BN, Fonseca MM, Machado-Vieira R, Soares JC, Kapczinski F.

Rev Bras Psiquiatr. 2004 Sep;26(3):180-8. Epub 2004 Nov 17. Review. Portuguese.

16.

Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3β signaling in bipolar patients.

Haenisch F, Alsaif M, Guest PC, Rahmoune H, Dickerson F, Yolken R, Bahn S.

J Affect Disord. 2014 Mar;156:139-43. doi: 10.1016/j.jad.2013.12.008. Epub 2013 Dec 16.

PMID:
24411062
17.

PP2A-Bgamma subunit and KCNQ2 K+ channels in bipolar disorder.

Borsotto M, Cavarec L, Bouillot M, Romey G, Macciardi F, Delaye A, Nasroune M, Bastucci M, Sambucy JL, Luan JJ, Charpagne A, Jouët V, Léger R, Lazdunski M, Cohen D, Chumakov I.

Pharmacogenomics J. 2007 Apr;7(2):123-32. Epub 2006 May 30.

PMID:
16733521
18.

Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD).

Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF.

Biol Psychiatry. 2003 Jun 1;53(11):1028-42. Review.

PMID:
12788248
19.

Neurobiology of bipolar disorder.

Newberg AR, Catapano LA, Zarate CA, Manji HK.

Expert Rev Neurother. 2008 Jan;8(1):93-110. Review.

PMID:
18088203
20.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk